No Data
KPC 2024 Annual Report
Summary of the 2024 Annual Report of KPC
KPC Pharmaceuticals, Inc. (600422.SH): In 2024, net income is expected to be 0.648 billion yuan, a year-on-year increase of 19.86%, planning to distribute 3 yuan per share.
GLG reported on March 11 that KPC Pharmaceuticals, Inc. (600422.SH) announced its 2024 annual report, which achieved revenue of 8.401 billion yuan during the reporting period, a year-on-year decrease of 0.34%; net income attributable to the shareholders of the listed company was 0.648 billion yuan, an increase of 19.86% year-on-year; basic EPS was 0.86 yuan. The company plans to distribute a cash dividend of 3.0 yuan (including tax) for every 10 shares to all shareholders.
A Piece Of The Puzzle Missing From KPC Pharmaceuticals,Inc.'s (SHSE:600422) Share Price
KPC Pharmaceuticals Gets Approval for Post-Surgery Delirium Drug Trial
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
KPC Pharmaceuticals,Inc (SHSE:600422) Not Lagging Market On Growth Or Pricing
